1.
Retroperitoneoscopic lumbar sympathectomy for diabetic necrotic foot:one case report
腹膜后腔镜腰交感神经切除术治疗糖尿病坏死足1例报告
2.
diabetic lipoidic necrobiosis
糖尿病脂性渐进性坏死
3.
necrobiosis lipoidica diabeticorum
糖尿病类脂性渐进性坏死症
4.
The Study on the Pathogenesy of Diabetic Avascular Necrosis of Femoral Head;
糖尿病性股骨头缺血坏死发病机制的研究
5.
Clinical Study of "XiaoJu Ⅰ" on Treating the Disorder of Microcirculation of Diabetic Foot Gangrene;
“消疽1号”对糖尿病足坏疽微循环变化临床研究
6.
Experimental Study of Diabetes and Avascular Necrosis of Femoral Head;
糖尿病与股骨头缺血性坏死关系的实验研究
7.
The Role of HbA1c and TNF-α in GDM;
糖化血红蛋白和肿瘤坏死因子与妊娠期糖尿病的关系
8.
Relation between Adiponectin, TNF-α and Type 2 Diabetes Mellitus with Coronary Heart Disease;
脂联素、肿瘤坏死因子α与2型糖尿病合并冠心病关系的研究
9.
The Expression of TNF-α、IGF-1 in Diabetic Cardiomyopathy;
肿瘤坏死因子-α、胰岛素样生长因子-1在糖尿病心肌病变中的表达
10.
The Study of Adiponectin and TNF-α in the Etiopathogenisis of Gestational Diabetes Mellitus;
脂联素与肿瘤坏死因子-α在妊娠期糖尿病发病中的研究
11.
A Preliminary Study on the Relationship between Adiponectin、TNF-α and Diabetic Retinopathy in DM Rats;
脂联素、肿瘤坏死因子-α与实验性糖尿病大鼠视网膜病变的关系
12.
A Preliminary Study on the Relationship between Adopnnectin、TNF-α and Diabetic Nephropathy in DM Rats;
脂联素、肿瘤坏死因子-α与实验性糖尿病大鼠肾脏病变的关系
13.
The Expression of APN、TNF-α in Diabetic Cardiomyopathy of DM Rats;
脂联素和肿瘤坏死因子-α在糖尿病大鼠心肌病变中的变化
14.
Analyst of Associations Between TNF-α and Coronary Heart Disease Accompanying Diabetes Mellitus
冠心病并发糖尿病患者血清肿瘤坏死因子水平的意义
15.
Expression of Tumor Necrosis Factor α and Tumor Necrosis Factor-alpha-converting Enzyme Gene in Myocardial Tissue with Diabetic Cardiomyopathy Rat;
肿瘤坏死因子α和肿瘤坏死因子转化酶基因在糖尿病性心肌病大鼠心肌中的表达
16.
The Detection and Meaning of Plasma Adiponectin and TNF-α in Nondiabetic First-degree Relatives of Type 2 Diabetes;
2型糖尿病患者非糖尿病一级亲属血浆脂联素和肿瘤坏死因子-α测定及其意义探讨
17.
Clinical Research on the Treatment of Wet Gangrene of Diabetes Foot by Washing with Jieduxiyao
解毒洗药外洗治疗糖尿病足湿性坏疽的临床研究
18.
The choice about the indication of interventional therapy in Diabetes Foot combining with the arteriosclerosis occlusion in lower limbs
糖尿病足坏疽合并下肢动脉硬化闭塞症介入治疗适应证的选择